Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

10.1056/NEJM199402173300709

Barlogie B, 1997, Clin Cancer Res, 3, 2605

10.1056/NEJM199607113350204

Barlogie B, 1997, Blood, 89, 789, 10.1182/blood.V89.3.789

Tricot G, 1995, Bone Marrow Transplant, 16, 7

Singhal S, 1996, Blood, 88, 611a

10.1007/BF00192885

10.1038/nm0195-27

10.1073/pnas.91.9.4082

10.1006/exer.1997.0292

10.1111/j.1365-2141.1994.tb08304.x

10.1002/ajh.2830500103

10.3109/10428199509054750

Munshi N, 1998, Blood, 92, 98a

10.1038/sj/leu/2401336

Vacca A, 1999, Blood, 93, 3064, 10.1182/blood.V93.9.3064

Olson KB, 1965, Clin Pharmacol Ther, 6, 292, 10.1002/cpt196563292

Greipp PR, 1987, Mayo Clin Proc, 62, 969, 10.1016/S0025-6196(12)65066-6

Bartl R, 1987, Am J Clin Pathol, 87, 342, 10.1093/ajcp/87.3.342

Tricot G, 1995, Blood, 86, 4250, 10.1182/blood.V86.11.4250.bloodjournal86114250

10.2307/2290318

10.2307/2281868

Mantel N, 1966, Cancer Chemother Rep, 50, 163

10.2307/2530695

10.1016/0162-3109(95)00050-X

10.1084/jem.173.3.699

Corral LG, 1996, Mol Med, 2, 506, 10.1007/BF03401909

10.1084/jem.187.11.1885

10.1111/j.1365-2249.1995.tb05527.x

Yaccoby S, 1998, Blood, 92, 2908, 10.1182/blood.V92.8.2908

10.1097/00001813-199605000-00015

Figg WD, 1997, Proc Am Soc Clin Oncol, 16, 333a

Fine HA, 1997, Proc Am Soc Clin Oncol, 16, 385a

Long G, 1998, Proc Am Soc Clin Oncol, 17, 181a

Eisen T, 1998, Proc Am Soc Clin Oncol, 17, 441a

Barlogie B, 1998, Blood, 92, 273b, 10.1182/blood.V92.1.273.413a32_273_282

Nguyen M, 1997, Int J Oncol, 10, 965